Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Correction: MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment.

Yuan H, Wang X, Lu J, Zhang Q, Brandina I, Alexandrov I, Glazer RI.

Oncotarget. 2018 Dec 28;9(102):37808. doi: 10.18632/oncotarget.26548. eCollection 2018 Dec 28.

2.

Erratum: Drug-Targeted Inhibition of Peroxisome Proliferator-Activated Receptor-gamma Enhances the Chemopreventive Effect of Anti-Estrogen Therapy.

Yuan H, Kopelovich L, Yin Y, Lu J, Glazer RI.

Oncotarget. 2018 Sep 18;9(73):33866. doi: 10.18632/oncotarget.26161. eCollection 2018 Sep 18.

3.

Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis.

Yuan H, Wang X, Shi C, Jin L, Hu J, Zhang A, Li J, Vijayendra N, Doodala V, Weiss S, Tang Y, Weiner LM, Glazer RI.

Sci Rep. 2018 Apr 9;8(1):5717. doi: 10.1038/s41598-018-24022-w.

4.

MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment.

Yuan H, Wang X, Lu J, Zhang Q, Brandina I, Alexandrov I, Glazer RI.

Oncotarget. 2018 Jan 15;9(8):8042-8053. doi: 10.18632/oncotarget.24233. eCollection 2018 Jan 30. Erratum in: Oncotarget. 2018 Dec 28;9(102):37808.

5.

PLAC1 as a serum biomarker for breast cancer.

Yuan H, Chen V, Boisvert M, Isaacs C, Glazer RI.

PLoS One. 2018 Feb 12;13(2):e0192106. doi: 10.1371/journal.pone.0192106. eCollection 2018.

6.

PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer.

Glazer RI, Kopelovich L.

Oncotarget. 2017 Apr 20;8(31):50337-50341. doi: 10.18632/oncotarget.17302. eCollection 2017 Aug 1.

7.

PPARδ as a Metabolic Initiator of Mammary Neoplasia and Immune Tolerance.

Glazer RI.

PPAR Res. 2016;2016:3082340. doi: 10.1155/2016/3082340. Epub 2016 Dec 18. Review.

8.

3D Bioprinting a Cell-Laden Bone Matrix for Breast Cancer Metastasis Study.

Zhou X, Zhu W, Nowicki M, Miao S, Cui H, Holmes B, Glazer RI, Zhang LG.

ACS Appl Mater Interfaces. 2016 Nov 9;8(44):30017-30026. Epub 2016 Oct 28.

PMID:
27766838
9.

A 3D printed nano bone matrix for characterization of breast cancer cell and osteoblast interactions.

Zhu W, Castro NJ, Cui H, Zhou X, Boualam B, McGrane R, Glazer RI, Zhang LG.

Nanotechnology. 2016 Aug 5;27(31):315103. Epub 2016 Jun 27.

10.

3D printed nanocomposite matrix for the study of breast cancer bone metastasis.

Zhu W, Holmes B, Glazer RI, Zhang LG.

Nanomedicine. 2016 Jan;12(1):69-79. doi: 10.1016/j.nano.2015.09.010. Epub 2015 Oct 22.

PMID:
26472048
11.

Efficacy of N-methanocarbathymidine against genital herpes simplex virus type 2 shedding and infection in guinea pigs.

Bernstein DI, Bravo FJ, Pullum DA, Shen H, Wang M, Rahman A, Glazer RI, Cardin RD.

Antivir Chem Chemother. 2015 Feb;24(1):19-27. doi: 10.1177/2040206614566581.

12.

Multifactorial analysis of conditional reprogramming of human keratinocytes.

Ligaba SB, Khurana A, Graham G, Krawczyk E, Jablonski S, Petricoin EF, Glazer RI, Upadhyay G.

PLoS One. 2015 Feb 25;10(2):e0116755. doi: 10.1371/journal.pone.0116755. eCollection 2015.

13.

PPARδ induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation.

Yuan H, Lu J, Xiao J, Upadhyay G, Umans R, Kallakury B, Yin Y, Fant ME, Kopelovich L, Glazer RI.

Cancer Res. 2013 Jul 15;73(14):4349-61. doi: 10.1158/0008-5472.CAN-13-0322. Epub 2013 Jun 27.

14.

Musashi1 as a potential therapeutic target and diagnostic marker for lung cancer.

Wang XY, Yu H, Linnoila RI, Li L, Li D, Mo B, Okano H, Penalva LO, Glazer RI.

Oncotarget. 2013 May;4(5):739-50.

16.

The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature.

Yuan H, Upadhyay G, Lu J, Kopelovich L, Glazer RI.

Cancer Prev Res (Phila). 2012 May;5(5):754-64. doi: 10.1158/1940-6207.CAPR-11-0526. Epub 2012 Mar 16.

17.

Musashi1: an RBP with versatile functions in normal and cancer stem cells.

Glazer RI, Vo DT, Penalva LO.

Front Biosci (Landmark Ed). 2012 Jan 1;17:54-64. Review.

PMID:
22201732
18.

Stem cell antigen-1 deficiency enhances the chemopreventive effect of peroxisome proliferator-activated receptorγ activation.

Yuan H, Upadhyay G, Yin Y, Kopelovich L, Glazer RI.

Cancer Prev Res (Phila). 2012 Jan;5(1):51-60. doi: 10.1158/1940-6207.CAPR-11-0256. Epub 2011 Sep 28.

19.

VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.

Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM, Brown ML, Toretsky JA, Uren A, Lee Y, MacDonald TJ, Rodriguez O, Glazer RI, Schlegel R, Albanese C.

Cancer Biol Ther. 2011 Nov 1;12(9):818-26. doi: 10.4161/cbt.12.9.17682. Epub 2011 Nov 1.

20.

Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)-dependent TGF-beta signaling.

Upadhyay G, Yin Y, Yuan H, Li X, Derynck R, Glazer RI.

Proc Natl Acad Sci U S A. 2011 May 10;108(19):7820-5. doi: 10.1073/pnas.1103441108. Epub 2011 Apr 25.

21.

Induction of metastatic gastric cancer by peroxisome proliferator-activated receptorδ activation.

Pollock CB, Rodriguez O, Martin PL, Albanese C, Li X, Kopelovich L, Glazer RI.

PPAR Res. 2010;2010:571783. doi: 10.1155/2010/571783. Epub 2010 Dec 27.

22.
23.

PPARδ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesis.

Pollock CB, Yin Y, Yuan H, Zeng X, King S, Li X, Kopelovich L, Albanese C, Glazer RI.

PLoS One. 2011 Jan 13;6(1):e16215. doi: 10.1371/journal.pone.0016215.

24.

Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival.

Wang XY, Penalva LO, Yuan H, Linnoila RI, Lu J, Okano H, Glazer RI.

Mol Cancer. 2010 Aug 21;9:221. doi: 10.1186/1476-4598-9-221.

25.

The IGF-I receptor can alter the matrix metalloproteinase repertoire of tumor cells through transcriptional regulation of PKC-{alpha}.

Li S, Zhang D, Yang L, Burnier JV, Wang N, Lin R, Lee ER, Glazer RI, Brodt P.

Mol Endocrinol. 2009 Dec;23(12):2013-25. doi: 10.1210/me.2009-0197. Epub 2009 Oct 23.

26.

A new mechanism of SOX9 action to regulate PKCalpha expression in the intestine epithelium.

Dupasquier S, Abdel-Samad R, Glazer RI, Bastide P, Jay P, Joubert D, Cavaillès V, Blache P, Quittau-Prévostel C.

J Cell Sci. 2009 Jul 1;122(Pt 13):2191-6. doi: 10.1242/jcs.036483. Epub 2009 Jun 9.

27.

A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1.

Rodriguez OC, Lai EW, Vissapragada S, Cromelin C, Avetian M, Salinas P, Ramos H, Kallakury B, Casimiro M, Lisanti MP, Tanowitz HB, Pacak K, Glazer RI, Avantaggiati M, Albanese C.

Am J Pathol. 2009 Jun;174(6):2051-60. doi: 10.2353/ajpath.2009.080859. Epub 2009 May 14.

28.

c-FLIPL regulates PKC via AP-2 to inhibit Bax-mediated apoptosis induced by HIV-1 gp120 in Jurkat cells.

Wang X, Zhao J, Tang S, Lee S, Glazer RI, Hewlett I.

Mol Cell Biochem. 2009 Oct;330(1-2):23-9. doi: 10.1007/s11010-009-0096-3. Epub 2009 Apr 11.

PMID:
19363595
29.

Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification.

Yin Y, Yuan H, Zeng X, Kopelovich L, Glazer RI.

Cancer Res. 2009 Jan 15;69(2):687-94. doi: 10.1158/0008-5472.CAN-08-2446.

30.

ErbB2 induces Notch1 activity and function in breast cancer cells.

Lindsay J, Jiao X, Sakamaki T, Casimiro MC, Shirley LA, Tran TH, Ju X, Liu M, Li Z, Wang C, Katiyar S, Rao M, Allen KG, Glazer RI, Ge C, Stanley P, Lisanti MP, Rui H, Pestell RG.

Clin Transl Sci. 2008 Sep;1(2):107-15. doi: 10.1111/j.1752-8062.2008.00041.x.

31.

Musashi1: a stem cell marker no longer in search of a function.

Glazer RI, Wang XY, Yuan H, Yin Y.

Cell Cycle. 2008 Sep 1;7(17):2635-9. Epub 2008 Sep 30. Review.

32.

PPARgamma and PPARdelta as Modulators of Neoplasia and Cell Fate.

Glazer RI, Yuan H, Xie Z, Yin Y.

PPAR Res. 2008;2008:247379. doi: 10.1155/2008/247379.

33.

Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways.

Wang XY, Yin Y, Yuan H, Sakamaki T, Okano H, Glazer RI.

Mol Cell Biol. 2008 Jun;28(11):3589-99. doi: 10.1128/MCB.00040-08. Epub 2008 Mar 24.

34.

Mammary stem and progenitor cell regulation.

Glazer RI, Wang X, Yuan H, Yin Y.

Cancer Biomark. 2007;3(4-5):171-81. Review.

PMID:
17917147
35.

Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus.

Smee DF, Hurst BL, Wong MH, Glazer RI, Rahman A, Sidwell RW.

Antiviral Res. 2007 Nov;76(2):124-9. Epub 2007 Jul 10.

36.

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM.

Genome Biol. 2007;8(5):R76.

37.
38.
39.

Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.

Koller E, Propp S, Zhang H, Zhao C, Xiao X, Chang M, Hirsch SA, Shepard PJ, Koo S, Murphy C, Glazer RI, Dean NM.

Cancer Res. 2006 Feb 15;66(4):2059-66.

40.

3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation.

Yin Y, Yuan H, Wang C, Pattabiraman N, Rao M, Pestell RG, Glazer RI.

Mol Endocrinol. 2006 Feb;20(2):268-78. Epub 2005 Sep 8.

PMID:
16150867
41.

Characterization of medroxyprogesterone and DMBA-induced multilineage mammary tumors by gene expression profiling.

Yin Y, Bai R, Russell RG, Beildeck ME, Xie Z, Kopelovich L, Glazer RI.

Mol Carcinog. 2005 Sep;44(1):42-50.

PMID:
15937957
42.

Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.

Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopelovich L, Glazer RI.

Cancer Res. 2005 May 1;65(9):3950-7. Erratum in: Cancer Res. 2005 Jul 1;65(13):5989. Cancer Res. 2005 Oct 1;65(19):9108. Kopleovich, Levy [corrected to Kopelovich, Levy].

43.

Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation.

Wei ZL, Petukhov PA, Bizik F, Teixeira JC, Mercola M, Volpe EA, Glazer RI, Willson TM, Kozikowski AP.

J Am Chem Soc. 2004 Dec 29;126(51):16714-5.

PMID:
15612696
44.

Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation.

Zhan M, Yu D, Liu J, Glazer RI, Hannay J, Pollock RE.

J Biol Chem. 2005 Feb 11;280(6):4825-33. Epub 2004 Nov 24. Erratum in: J Biol Chem. 2005 Jun 10;280(23):22555. Glazer, Robert I [added].

46.

Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents.

Kopelovich L, Fay JR, Glazer RI, Crowell JA.

Mol Cancer Ther. 2002 Mar;1(5):357-63. Review. Erratum in: Mol Cancer Ther. 2002 May;1(7):564.

47.

Modulation of the human protein kinase C alpha gene promoter by activator protein-2.

Clark JH, Haridasse V, Glazer RI.

Biochemistry. 2002 Oct 1;41(39):11847-56. Erratum in: Biochemistry 2002 Oct 29;41(43):13116.

PMID:
12269829
49.

Delayed mammary gland involution in MMTV-AKT1 transgenic mice.

Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI.

Oncogene. 2002 Jan 10;21(2):198-206.

50.

Supplemental Content

Loading ...
Support Center